Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iron protein acetyl aspartate (also known as Fe-ASP) is an oral iron supplement consisting of a ferroprotein complex where trivalent iron (Fe3+) is bound to casein via N-acetyl-aspartate linkages. Developed by Uni-Pharma SA and marketed under the brand name Omalin, it is indicated for the treatment of iron deficiency anemia (IDA). The casein-acetyl-aspartate coating protects the iron from the acidic environment of the stomach, preventing the formation of insoluble iron salts and reducing common gastrointestinal side effects such as nausea and epigastric pain. The complex remains stable until it reaches the duodenum, where it is enzymatically digested to release bioavailable iron for absorption. Clinical studies have demonstrated its efficacy in restoring hemoglobin and ferritin levels in various patient populations, including pregnant women, children, and geriatric patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iron protein acetylaspartate.